Drug Profile
Zuclomifene - Veru Healthcare
Alternative Names: APP 944; cis-clomifene; cis-clomiphene citrate; RMI-16312; VERU-944; Zuclomiphene citrateLatest Information Update: 07 Dec 2022
Price :
$50
*
At a glance
- Originator Aspen Park Pharmaceuticals
- Developer Veru Healthcare
- Class Antineoplastics; Infertility therapies; Small molecules
- Mechanism of Action Estrogen receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Hot flashes
Most Recent Events
- 07 Dec 2022 Zuclomifene is still in phase II trials for Hot flash in USA (Veru pipeline, December 2022)
- 17 Feb 2022 Veru Healthcare plans a phase IIb trial for Hot flashes (in patients with advanced prostate cancer undergoing androgen deprivation therapy) (PO)
- 19 Jun 2020 Veru, following an End of Phase 2 meeting, plans a phase III trial for Hot flashes (in patients with advanced prostate cancer) in late 2020